One Week Left for CTIS Mandatory Use Date

Moving towards the development of mature quality management systems.

Final guidance suggests sponsors select two doses for Phase II trials with additional data requirements.

Session provides insight as to how to boost interoperability and expand the middleware on a global scale.

The promise and acceptance of using this AI tool in drug development is growing.

Compliance with diverse clinical trial payment and data standards requires specialized skills.

Preventing delays and accelerating the progression of these critical therapies.